| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $98.6K | 0.00% | 165.22K | +308% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ATYR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 26, 2026 | Schimmel Paul R.Director | Purchase at price 0.50 per share. | 100K | $49.63K |
| Feb 3, 2026 | Broadfoot Jill MarieChief Financial Officer | Sale at price 0.98 per share. | 1.6K | $1.52K |
| Feb 3, 2026 | Shukla Sanjay SChief Executive Officer | Sale at price 0.98 per share. | 3.7K | $3.65K |
| Feb 3, 2026 | Denyes NancyGeneral Counsel | Sale at price 0.98 per share. | 1.1K | $1.09K |
| Feb 2, 2026 | Broadfoot Jill MarieChief Financial Officer | — | 3.8K | — |
| Feb 2, 2026 | Shukla Sanjay SChief Executive Officer | — | 10.4K | — |
| Feb 2, 2026 | Denyes NancyGeneral Counsel | — | 2.7K | — |
| Oct 8, 2025 | Schimmel Paul R.Director | Purchase at price 0.90 - 0.94 per share. | 1.00M | $911.80K |
| Mar 16, 2025 | Gross Jane ADirector | Purchase at price 4.00 per share. | 3.8K | $15.00K |
| Feb 3, 2025 | Broadfoot Jill MarieChief Financial Officer | Sale at price 3.78 per share. | 1.3K | $4.74K |
| Feb 3, 2025 | Denyes NancyGeneral Counsel | Sale at price 3.78 per share. | 899 | $3.40K |
| Feb 2, 2025 | Broadfoot Jill MarieChief Financial Officer | — | 3.8K | — |
| Feb 2, 2025 | Shukla Sanjay SChief Executive Officer | — | 10.4K | — |
| Feb 2, 2025 | Denyes NancyGeneral Counsel | — | 2.7K | — |
TimeframesDown on all 2 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.7 | 8.7 | -18.7 | 3.5 | -32.3 | 9.2 | -18.6 | 9.5 | -43.0 | -99.0 | −99.6% | ||
| 2025 | 6.6 | 2.5 | -23.6 | 14.9 | 28.8 | 13.4 | -6.9 | 14.0 | -86.6 | 20.0 | -9.9 | 0.3 | −78.4% |
| 2024 | 13.1 | 20.4 | 1.6 | -19.5 | 10.2 | -9.8 | 26.9 | -5.6 | -5.9 | 77.3 | 13.1 | 2.5 | +156.7% |
| 2023 | 5.0 | -8.3 | -0.5 | -7.1 | 16.4 | -4.8 | -9.3 | -13.3 | -7.1 | -20.9 | 4.0 | 8.5 | −35.6% |
| 2022 | -23.8 | -12.8 | 7.9 | -22.2 | -32.5 | 0.7 | 24.0 | -2.6 | -12.3 | -17.7 | -12.6 | 1.4 | −70.7% |
| 2021 | -5.4 | 18.5 | 2.3 | -9.0 | 12.1 | 7.5 | -4.5 | 18.3 | 64.6 | -5.4 | -2.9 | -10.4 | +92.5% |
| 2020 | 21.6 | -26.8 | -24.5 | 28.2 | 4.2 | 18.7 | -11.0 | -4.8 | -14.1 | -1.9 | 37.5 | -11.0 | −7.0% |
| 2019 | 1.1 | -4.2 | 14.6 | 12.9 | -30.4 | -15.2 | -31.6 | -16.2 | 19.0 | 3.1 | 33.8 | -13.7 | −39.9% |
| 2018 | 1.4 | -16.9 | -10.2 | -15.1 | -59.9 | 0.8 | -14.8 | -6.9 | 12.6 | -25.2 | 1.3 | -19.5 | −85.8% |
| 2017 | 53.5 | 21.2 | -12.5 | -5.7 | 0.0 | 3.0 | 1.5 | -11.6 | 65.6 | -5.0 | -18.8 | -10.3 | +62.8% |
| 2016 | -46.3 | -15.3 | -11.9 | -9.6 | -7.0 | -16.0 | 22.7 | -14.4 | 8.9 | -13.5 | 12.7 | -30.6 | −78.1% |
| 2015 | -19.1 | 1.2 | -22.8 | -29.1 | 21.4 | -31.7 | 15.5 | −57.1% |
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Buy / hold / sell counts